

IPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

File application of: Edward Ashton

Application No: 10/811,887

Filed: March 30, 2004

For: SYSTEM AND METHOD FOR IDENTIFYING OPTIMIZED BLOOD SIGNAL IN MEDICAL IMAGES TO ELIMINATE FLOW ARTIFACTS

Group Art Unit: 3739

Confirmation No. 1329

Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:


Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicant(s) wish to make of record the references listed on the attached form PTO/SB/08 (substitute for PTO-1449). Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

- ☒ This Information Disclosure Statement is being filed (a) within three months of the filing date of the subject patent application, OR (b) before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this statement. No fee is required.
- ☐ No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement. No fee is required.
- ☐ A check in the amount of \$180.00 is enclosed under 37 CFR §1.17(p).
- ☐ This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. A check in the amount of \$180.00 is enclosed under 37 CFR §1.17(p).
- ☐ Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.
- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 23-2185. A duplicate copy of this sheet is enclosed.

Blank Rome LLP  
600 New Hampshire Avenue, N.W.  
Washington, DC 20037  
Tel: (202) 772-5800  
Fax (202) 572-8398  
Customer No.: 27557  
Date: June 10, 2005

Respectfully submitted,

  
Michael C. Greenbaum  
Attorney of Record  
Registration No. 28,419



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/811,887
Filing Date	March 30, 2004
First Named Inventor	Edward Ashton
Art Unit	3739
Examiner Name	Unassigned
Attorney Docket Number	116741-00238

Sheet 1 of 1

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	01	Mark Rijpkema, et al. "Method for Quantitative Mapping of Dynamic MRI Contrast Agent Uptake in Human Tumors", Journal of Magnetic Resonance Imaging 14:457-463, 2001, pp. 457-463	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.